TY - JOUR AU - Craig, T. AU - Aygören-Pürsün, E. AU - Bork, K. AU - Bowen, T. AU - Boysen, H. AU - Farkas, H. PY - 2012 DA - 2012// TI - WAO guideline for the management of hereditary angioedema JO - World Allergy Organ J VL - 5 UR - https://doi.org/10.1097/WOX.0b013e318279affa DO - 10.1097/WOX.0b013e318279affa ID - Craig2012 ER - TY - JOUR AU - Bork, K. AU - Davis-Lorton, M. PY - 2013 DA - 2013// TI - Overview of hereditary angioedema caused by C1-inhibitor deficiency: assessment and clinical management JO - Eur Ann Allergy Clin Immunol VL - 45 ID - Bork2013 ER - TY - JOUR AU - Kaplan, A. P. AU - Joseph, K. PY - 2014 DA - 2014// TI - Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway JO - Adv Immunol VL - 121 UR - https://doi.org/10.1016/B978-0-12-800100-4.00002-7 DO - 10.1016/B978-0-12-800100-4.00002-7 ID - Kaplan2014 ER - TY - JOUR AU - Riedl, M. A. PY - 2015 DA - 2015// TI - Critical appraisal of androgen use in hereditary angioedema: a systematic review JO - Ann Allergy Asthma Immunol VL - 114 ID - Riedl2015 ER - TY - JOUR AU - Kenniston, J. A. AU - Faucette, R. R. AU - Martik, D. AU - Comeau, S. R. AU - Lindberg, A. P. AU - Kopacz, K. J. PY - 2014 DA - 2014// TI - Inhibition of plasma kallikrein by a highly specific, active site blocking antibody JO - J Biol Chem VL - 289 UR - https://doi.org/10.1074/jbc.M114.569061 DO - 10.1074/jbc.M114.569061 ID - Kenniston2014 ER - TY - JOUR AU - Chyung, Y. AU - Vince, B. AU - Iarrobino, R. AU - Sexton, D. AU - Kenniston, J. AU - Faucette, R. PY - 2014 DA - 2014// TI - A phase 1 study investigating DX-2930 in healthy subjects JO - Ann Allergy Asthma Immunol VL - 113 UR - https://doi.org/10.1016/j.anai.2014.05.028 DO - 10.1016/j.anai.2014.05.028 ID - Chyung2014 ER - TY - JOUR AU - Banerji, A. AU - Busse, P. AU - Shennak, M. AU - Lumry, W. AU - Davis-Lorton, M. AU - Wedner, H. J. PY - 2017 DA - 2017// TI - Inhibiting plasma kallikrein for hereditary angioedema prophylaxis JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMoa1605767 DO - 10.1056/NEJMoa1605767 ID - Banerji2017 ER - TY - STD TI - ClinicalTrials.gov. Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE. https://clinicaltrials.gov/ct2/show/NCT02586805. Accessed 10 Feb 2017. UR - https://clinicaltrials.gov/ct2/show/NCT02586805 ID - ref8 ER - TY - STD TI - ClinicalTrials.gov. Long-term Safety and Efficacy Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE. https://clinicaltrials.gov/ct2/show/NCT02741596. Accessed 10 Feb 2017. UR - https://clinicaltrials.gov/ct2/show/NCT02741596 ID - ref9 ER - TY - JOUR AU - Weller, K. AU - Groffik, A. AU - Magerl, M. AU - Tohme, N. AU - Martus, P. AU - Krause, K. PY - 2012 DA - 2012// TI - Development and construct validation of the angioedema quality of life questionnaire JO - Allergy VL - 67 UR - https://doi.org/10.1111/all.12007 DO - 10.1111/all.12007 ID - Weller2012 ER - TY - JOUR AU - Herdman, M. AU - Gudex, C. AU - Lloyd, A. AU - Janssen, M. AU - Kind, P. AU - Parkin, D. PY - 2011 DA - 2011// TI - Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) JO - Qual Life Res VL - 20 UR - https://doi.org/10.1007/s11136-011-9903-x DO - 10.1007/s11136-011-9903-x ID - Herdman2011 ER - TY - JOUR AU - Reilly, M. C. AU - Zbrozek, A. S. AU - Dukes, E. M. PY - 1993 DA - 1993// TI - The validity and reproducibility of a work productivity and activity impairment instrument JO - Pharmacoeconomics VL - 4 UR - https://doi.org/10.2165/00019053-199304050-00006 DO - 10.2165/00019053-199304050-00006 ID - Reilly1993 ER - TY - JOUR AU - Zigmond, A. S. AU - Snaith, R. P. PY - 1983 DA - 1983// TI - The hospital anxiety and depression scale JO - Acta Psychiatr Scand VL - 67 UR - https://doi.org/10.1111/j.1600-0447.1983.tb09716.x DO - 10.1111/j.1600-0447.1983.tb09716.x ID - Zigmond1983 ER - TY - JOUR AU - Ware, J. AU - Kosinski, M. AU - Keller, S. D. PY - 1996 DA - 1996// TI - A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity JO - Med Care VL - 34 UR - https://doi.org/10.1097/00005650-199603000-00003 DO - 10.1097/00005650-199603000-00003 ID - Ware1996 ER - TY - JOUR AU - Li, H. H. PY - 2016 DA - 2016// TI - Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptance JO - Patient Prefer Adherence VL - 10 UR - https://doi.org/10.2147/PPA.S86379 DO - 10.2147/PPA.S86379 ID - Li2016 ER - TY - JOUR AU - Wang, A. AU - Fouche, A. AU - Craig, T. J. PY - 2015 DA - 2015// TI - Patients perception of self-administrated medication in the treatment of hereditary angioedema JO - Ann Allergy Asthma Immunol VL - 115 UR - https://doi.org/10.1016/j.anai.2015.06.006 DO - 10.1016/j.anai.2015.06.006 ID - Wang2015 ER - TY - JOUR AU - Zuraw, B. L. AU - Busse, P. J. AU - White, M. AU - Jacobs, J. AU - Lumry, W. AU - Baker, J. PY - 2010 DA - 2010// TI - Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa0805538 DO - 10.1056/NEJMoa0805538 ID - Zuraw2010 ER - TY - JOUR AU - Zuraw, B. L. AU - Kalfus, I. PY - 2012 DA - 2012// TI - Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema JO - Am J Med VL - 125 UR - https://doi.org/10.1016/j.amjmed.2012.02.020 DO - 10.1016/j.amjmed.2012.02.020 ID - Zuraw2012 ER - TY - JOUR AU - Gandhi, P. K. AU - Gentry, W. M. AU - Bottorff, M. B. PY - 2012 DA - 2012// TI - Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database JO - Pharmacotherapy VL - 32 UR - https://doi.org/10.1002/j.1875-9114.2012.01126 DO - 10.1002/j.1875-9114.2012.01126 ID - Gandhi2012 ER - TY - JOUR AU - Bernstein, J. A. AU - Manning, M. E. AU - Li, H. AU - White, M. V. AU - Baker, J. AU - Lumry, W. R. PY - 2014 DA - 2014// TI - Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema JO - J Allergy Clin Immunol Pract VL - 2 UR - https://doi.org/10.1016/j.jaip.2013.09.008 DO - 10.1016/j.jaip.2013.09.008 ID - Bernstein2014 ER - TY - JOUR AU - Bork, K. AU - Bygum, A. AU - Hardt, J. PY - 2008 DA - 2008// TI - Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients JO - Ann Allergy Asthma Immunol VL - 100 UR - https://doi.org/10.1016/S1081-1206(10)60424-3 DO - 10.1016/S1081-1206(10)60424-3 ID - Bork2008 ER - TY - JOUR AU - Wintenberger, C. AU - Boccon-Gibod, I. AU - Launay, D. AU - Fain, O. AU - Kanny, G. AU - Jeandel, P. Y. PY - 2014 DA - 2014// TI - Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients JO - Clin Exp Immunol VL - 178 UR - https://doi.org/10.1111/cei.12379 DO - 10.1111/cei.12379 ID - Wintenberger2014 ER -